Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2010

View Archived Issues

Actelion Pharma discloses new orexin receptor antagonists

Achaogen describes new tobramycin derivatives

Tetraphase Pharmaceuticals claims new antibacterial compounds

Amplyx Pharmaceuticals divulges novel HIV protease inhibitors

Repligen receives grant to support RG-3039 program for spinal muscular atrophy

New ICAM-1/VCAM-1-targeting nanocarriers developed for ocular neovascularization therapies

Simvastatin may stabilize visual field in normal-tension glaucoma

Recordati and Nymox sign licensing agreement for NX-1207 in BPH

Bayer HealthCare submits European application for new YAZ-based oral contraceptive regimen

EMA recommends approval of Xiapex for treatment of Dupuytren's contracture

FDA clears phase Ia trial of NSI-189 for treatment of depression

FDA clears phase I trial of respiratory syncytial virus vaccine RSV-F

Amarin provides update on phase III ANCHOR trial

Anacor begins phase III AN-2690 trial in onychomycosis

FDA issues complete response letter to AstraZeneca for Brilinta

Merck KGaA and sanofi-aventis to jointly investigate new anticancer agents

MM-302 shows promise to treat HER2-overexpressing tumors

Genentech provides update on Avastin for metastatic breast cancer

CK-2017357 leads to functional improvement in ALS

Repros Therapeutics provides update on low-dose Proellex trial

Novel Toll-like receptor 7 agonists discovered

Children's Hospital Boston begins mecasermin trial in Rett's syndrome

Canadian researchers identify new methyl sulfanyl pyrmidines

Amira Pharma nominates preclinical candidate in LPA-related program

Enzon and NCI begin phase I trials of EZN-2968 and EZN-2208

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...